SCHEMBL6031371

SCHEMBL6031371

CCCCCCCCCCOC(=O)Nc1sc(CCCCCCCC)cc1C(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.55
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.42
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CSNK2A2 P19784 2/20 0.39
CSNK2A1 P68400 2/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
EPHX1 P07099 1/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
REV1 Q9UBZ9 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031127 1.00 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6030817 1.00 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6029945 1.00 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6030807 1.00 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6031818 0.98 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6031071 0.98 HSD17B10 (0.55) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6029706 0.94 HSD17B10 (0.56) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6030542 0.93 HSD17B10 (0.51) HSD17B10RXFP1ALDH1A1KDM4EMAPT
SCHEMBL6030980 0.92 HSD17B10 (0.47) HSD17B10MAPTSMN1; SMN2GAA
SCHEMBL6030453 0.92 HSD17B10 (0.47) HSD17B10MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL HSD17B10 126/4885RXFP1 612/4885ALDH1A1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.